WNTRESEARCH

wntresearch-logo

WntResearch AB develops anti-metastatic therapies for the treatment of cancer patients. The company’s products include Foxy-5, a small peptide, which is in Phase I clinical stage development for reconstituting the effect of Wnt-5a in breast cancer cells; and Box-5 peptide that is in preclinical phase for antagonizing the effects of Wnt-5a. WntResearch AB was founded in 2007 and is based in Malmö, Sweden.

#SimilarOrganizations #People #Website #More

WNTRESEARCH

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2007-01-01

Address:
Malmö, Skane Lan, Sweden

Country:
Sweden

Website Url:
http://www.wntresearch.com

Total Employee:
11+

Status:
Active

Contact:
46 4 06 50 18 40

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Apache Wordpress Plugins


Similar Organizations

karveel-pharmaceuticals-logo

Karveel Pharmaceuticals

Karveel Pharmaceuticals develops antibiotics for the treatment of serious drug-resistant infections.

oncozenge-logo

OncoZenge

OncoZenge develops better products for the supportive care of cancer patients.

win-consortium-logo

WIN Consortium

WIN Consortium is on mission to accelerate the pace and reduce the cost of translating novel cancer treatments.

Current Employees Featured

dennis-henriksen_image

Dennis Henriksen
Dennis Henriksen CTO @ WntResearch
CTO
2015-08-01

pernilla-sandwall_image

Pernilla Sandwall
Pernilla Sandwall CEO @ WntResearch
CEO
2022-01-01

Official Site Inspections

http://www.wntresearch.com

  • Host name: nestil-srv01.oderland.com
  • IP address: 46.16.234.137
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...

More informations about "WntResearch"

WntResearch - Crunchbase Company Profile & Funding

WntResearch AB develops anti-metastatic therapies for the treatment of cancer patients. The company’s products include Foxy-5, a small peptide, which is in Phase I clinical stage development for reconstituting the effect of Wnt-5a in breast cancer cells; and Box-5 peptide …See details»

WNTresearch – WNT research

A new approach to fight tumour spread! Foxy-5 is a unique drug candidate: Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profileSee details»

Wntresearch AB - Drug pipelines, Patents, Clinical trials - Synapse

WntResearch has identified a formylated 6 amino acid peptide fragment, named Foxy-5, which mimick the effects of Wnt-5a to impair migration of epithelial cancer cells and thereby acting anti-metastatic. ... The statistics for drugs in the Pipeline is the current organization and its …See details»

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company’s research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells’ ability to move and spread …See details»

WntResearch Company Profile - Office Locations, Competitors

WntResearch is a biotech company that develops therapies for preventing cancer spread. It offers anti-metastatic therapies that limit the ability of cancer cells to separate from the tumor and spread in the body to avoid metastasis. Type Public Status Active Founded 2007 HQSee details»

Wntresearch - Overview, News & Competitors | ZoomInfo.com

WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no …See details»

WntResearch CEO and Key Executive Team | Craft.co

WntResearch's Board Member is Jan Nilsson. Other executives include Tommy Andersson, Board Member; Klaus Christensen, CCO and 3 others. See the full leadership team at Craft.See details»

WntResearch Company Profile 2024: Stock Performance

What is WntResearch’s annual earnings per share (EPS)? WntResearch’s EPS for 12 months was -$0.65. Data Transparency. Meet our data hygiene team. Discover how our experts ensure you’re getting the most accurate financial data in the industry.See details»

WntResearch AB - LinkedIn

WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Skip ...See details»

WntResearch AB (WNT.ST) Company Profile & Facts - Yahoo Finance

See the company profile for WntResearch AB (WNT.ST) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»

WntResearch AB (NGM: WNT) - Stock Analysis

Dec 12, 2024 WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer.See details»

Wntresearch AB, WNT:AKT profile - FT.com - Financial Times

Nov 29, 2024 Wntresearch AB (WNT:AKT) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»

Company WntResearch AB - MarketScreener.com

Sep 17, 2009 Business description: WntResearch AB WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic …See details»

WntResearch - VentureRadar

WntResearch has gained international renown as the only company in the world to develop a drug that both combats metastasis and enables hormone treatment of breast cancer tumours. Hormone treatments are more humane and have fewer side-effects than chemotherapy, but …See details»

WntResearch AB Stock - MarketScreener.com

5 days ago WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small …See details»

WntResearch - Contacts, Employees, Board Members, Advisors

Organization. WntResearch . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... WntResearch has 2 current employee profiles, including CTO Dennis Henriksen. WntResearch has 1 board member or advisor, Christer Nordstedt. …See details»

Wntresearch AB, WNT:AKT summary - FT.com - Financial Times

Sep 13, 2024 WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process an d the evaluation of …See details»

Press releases - WNTresearch

WntResearch genomför företrädesemission som tecknas till cirka 55,9%, vilket tillför bolaget cirka 31,4....Read More. 22. WntResearch AB: Delårsrapport januari-mars 2024. Published on : 2024/05/03. Väsentliga händelser första kvartalet WntResearchs reviderade studieplan för den …See details»

WntResearch aktie | WNT | Aktiekurs, analyser & nyheter - Börskollen

Om Börskollen. Börskollen är en prisvinnande nyhetstidning och tjänst för börsintresserade som grundades 2015. Idag drivs tjänsten primärt av Kristoffer och Daniel.Båda har stor erfarenhet av börsen, aktier, investeringar, privatekonomi, företagande och motorrelaterat – ämnen som det …See details»

linkstock.net © 2022. All rights reserved